Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe

Results of a European concerted action

Christian Bréchot, Franck Jaffredo, David Lagorce, Guido Gerken, Karl Meyer Zum Büschenfelde, Anastasia Papakonstontinou, Stephanos Hadziyannis, Raffaela Romeo, Massimo Colombo, Joan Rodes, Jordi Bruix, Roger Williams, Nikolai Naoumov

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Background/Aims: To investigate the impact of hepatitis B (HBV) and C (HCV) infections on hepatocellular carcinoma (HCC) in Europe. Methods: Five hundred and three patients with HCC, from six liver centers, were included. All 503 sera and 80 liver samples were tested for HBV DNA and HCV RNA by polymerase chain reaction. GBV-C/HGV RNA was also tested in 57 sera. Results: HBsAg and anti-HCV were detected in 19% and 40.1% of the patients, respectively. Serum and liver HBV DNA were detected in 82% and 91% of the HBsAg positive subjects. HBV DNA was also detected in the serum and liver of 33% and 47% of HBsAg negative patients. In this group, serum HBV DNA was more prevalent in anti-HBs and/or anti-HBc patients (47.9%), compared to those without any HBV marker (25.1%). HCV RNA was detected in 89% and 7% of anti- HCV positive and negative cases, respectively, HCV 1b being the most prevalent genotype (80%). Coinfection with HBV and HCV was shown in 20.4% of patients, while only 29% had neither HBV nor HCV. GBV-C/HGV RNA was detected in only 4/57 sera. Conclusions: This study offers the first large analysis of HCC in Europe, based on both serology and molecular tests. It demonstrates the major impact of HBV and HCV, but not of GBV-C/HGV, in liver carcinogenesis in Northern as well as Southern Europe. It also stresses the need to use viral genome detection in epidemiological studies when serological tests are negative.

Original languageEnglish
Pages (from-to)173-183
Number of pages11
JournalJournal of Hepatology
Volume29
Issue number2
DOIs
Publication statusPublished - Aug 1998

Fingerprint

GB virus C
Hepatocellular Carcinoma
Hepatitis B Surface Antigens
Serum
Liver
DNA
RNA
Viral Genome
Serologic Tests
Serology
DNA-Directed RNA Polymerases
Hepatitis C
Hepatitis B
Coinfection
Epidemiologic Studies
Carcinogenesis
Genotype
Polymerase Chain Reaction
Infection

Keywords

  • HBV
  • HCC
  • HCV
  • HGV

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Bréchot, C., Jaffredo, F., Lagorce, D., Gerken, G., Zum Büschenfelde, K. M., Papakonstontinou, A., ... Naoumov, N. (1998). Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: Results of a European concerted action. Journal of Hepatology, 29(2), 173-183. https://doi.org/10.1016/S0168-8278(98)80001-9

Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe : Results of a European concerted action. / Bréchot, Christian; Jaffredo, Franck; Lagorce, David; Gerken, Guido; Zum Büschenfelde, Karl Meyer; Papakonstontinou, Anastasia; Hadziyannis, Stephanos; Romeo, Raffaela; Colombo, Massimo; Rodes, Joan; Bruix, Jordi; Williams, Roger; Naoumov, Nikolai.

In: Journal of Hepatology, Vol. 29, No. 2, 08.1998, p. 173-183.

Research output: Contribution to journalArticle

Bréchot, C, Jaffredo, F, Lagorce, D, Gerken, G, Zum Büschenfelde, KM, Papakonstontinou, A, Hadziyannis, S, Romeo, R, Colombo, M, Rodes, J, Bruix, J, Williams, R & Naoumov, N 1998, 'Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: Results of a European concerted action', Journal of Hepatology, vol. 29, no. 2, pp. 173-183. https://doi.org/10.1016/S0168-8278(98)80001-9
Bréchot C, Jaffredo F, Lagorce D, Gerken G, Zum Büschenfelde KM, Papakonstontinou A et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: Results of a European concerted action. Journal of Hepatology. 1998 Aug;29(2):173-183. https://doi.org/10.1016/S0168-8278(98)80001-9
Bréchot, Christian ; Jaffredo, Franck ; Lagorce, David ; Gerken, Guido ; Zum Büschenfelde, Karl Meyer ; Papakonstontinou, Anastasia ; Hadziyannis, Stephanos ; Romeo, Raffaela ; Colombo, Massimo ; Rodes, Joan ; Bruix, Jordi ; Williams, Roger ; Naoumov, Nikolai. / Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe : Results of a European concerted action. In: Journal of Hepatology. 1998 ; Vol. 29, No. 2. pp. 173-183.
@article{d78bc2a5b8834c2cb397620046bc2605,
title = "Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: Results of a European concerted action",
abstract = "Background/Aims: To investigate the impact of hepatitis B (HBV) and C (HCV) infections on hepatocellular carcinoma (HCC) in Europe. Methods: Five hundred and three patients with HCC, from six liver centers, were included. All 503 sera and 80 liver samples were tested for HBV DNA and HCV RNA by polymerase chain reaction. GBV-C/HGV RNA was also tested in 57 sera. Results: HBsAg and anti-HCV were detected in 19{\%} and 40.1{\%} of the patients, respectively. Serum and liver HBV DNA were detected in 82{\%} and 91{\%} of the HBsAg positive subjects. HBV DNA was also detected in the serum and liver of 33{\%} and 47{\%} of HBsAg negative patients. In this group, serum HBV DNA was more prevalent in anti-HBs and/or anti-HBc patients (47.9{\%}), compared to those without any HBV marker (25.1{\%}). HCV RNA was detected in 89{\%} and 7{\%} of anti- HCV positive and negative cases, respectively, HCV 1b being the most prevalent genotype (80{\%}). Coinfection with HBV and HCV was shown in 20.4{\%} of patients, while only 29{\%} had neither HBV nor HCV. GBV-C/HGV RNA was detected in only 4/57 sera. Conclusions: This study offers the first large analysis of HCC in Europe, based on both serology and molecular tests. It demonstrates the major impact of HBV and HCV, but not of GBV-C/HGV, in liver carcinogenesis in Northern as well as Southern Europe. It also stresses the need to use viral genome detection in epidemiological studies when serological tests are negative.",
keywords = "HBV, HCC, HCV, HGV",
author = "Christian Br{\'e}chot and Franck Jaffredo and David Lagorce and Guido Gerken and {Zum B{\"u}schenfelde}, {Karl Meyer} and Anastasia Papakonstontinou and Stephanos Hadziyannis and Raffaela Romeo and Massimo Colombo and Joan Rodes and Jordi Bruix and Roger Williams and Nikolai Naoumov",
year = "1998",
month = "8",
doi = "10.1016/S0168-8278(98)80001-9",
language = "English",
volume = "29",
pages = "173--183",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe

T2 - Results of a European concerted action

AU - Bréchot, Christian

AU - Jaffredo, Franck

AU - Lagorce, David

AU - Gerken, Guido

AU - Zum Büschenfelde, Karl Meyer

AU - Papakonstontinou, Anastasia

AU - Hadziyannis, Stephanos

AU - Romeo, Raffaela

AU - Colombo, Massimo

AU - Rodes, Joan

AU - Bruix, Jordi

AU - Williams, Roger

AU - Naoumov, Nikolai

PY - 1998/8

Y1 - 1998/8

N2 - Background/Aims: To investigate the impact of hepatitis B (HBV) and C (HCV) infections on hepatocellular carcinoma (HCC) in Europe. Methods: Five hundred and three patients with HCC, from six liver centers, were included. All 503 sera and 80 liver samples were tested for HBV DNA and HCV RNA by polymerase chain reaction. GBV-C/HGV RNA was also tested in 57 sera. Results: HBsAg and anti-HCV were detected in 19% and 40.1% of the patients, respectively. Serum and liver HBV DNA were detected in 82% and 91% of the HBsAg positive subjects. HBV DNA was also detected in the serum and liver of 33% and 47% of HBsAg negative patients. In this group, serum HBV DNA was more prevalent in anti-HBs and/or anti-HBc patients (47.9%), compared to those without any HBV marker (25.1%). HCV RNA was detected in 89% and 7% of anti- HCV positive and negative cases, respectively, HCV 1b being the most prevalent genotype (80%). Coinfection with HBV and HCV was shown in 20.4% of patients, while only 29% had neither HBV nor HCV. GBV-C/HGV RNA was detected in only 4/57 sera. Conclusions: This study offers the first large analysis of HCC in Europe, based on both serology and molecular tests. It demonstrates the major impact of HBV and HCV, but not of GBV-C/HGV, in liver carcinogenesis in Northern as well as Southern Europe. It also stresses the need to use viral genome detection in epidemiological studies when serological tests are negative.

AB - Background/Aims: To investigate the impact of hepatitis B (HBV) and C (HCV) infections on hepatocellular carcinoma (HCC) in Europe. Methods: Five hundred and three patients with HCC, from six liver centers, were included. All 503 sera and 80 liver samples were tested for HBV DNA and HCV RNA by polymerase chain reaction. GBV-C/HGV RNA was also tested in 57 sera. Results: HBsAg and anti-HCV were detected in 19% and 40.1% of the patients, respectively. Serum and liver HBV DNA were detected in 82% and 91% of the HBsAg positive subjects. HBV DNA was also detected in the serum and liver of 33% and 47% of HBsAg negative patients. In this group, serum HBV DNA was more prevalent in anti-HBs and/or anti-HBc patients (47.9%), compared to those without any HBV marker (25.1%). HCV RNA was detected in 89% and 7% of anti- HCV positive and negative cases, respectively, HCV 1b being the most prevalent genotype (80%). Coinfection with HBV and HCV was shown in 20.4% of patients, while only 29% had neither HBV nor HCV. GBV-C/HGV RNA was detected in only 4/57 sera. Conclusions: This study offers the first large analysis of HCC in Europe, based on both serology and molecular tests. It demonstrates the major impact of HBV and HCV, but not of GBV-C/HGV, in liver carcinogenesis in Northern as well as Southern Europe. It also stresses the need to use viral genome detection in epidemiological studies when serological tests are negative.

KW - HBV

KW - HCC

KW - HCV

KW - HGV

UR - http://www.scopus.com/inward/record.url?scp=0032145740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032145740&partnerID=8YFLogxK

U2 - 10.1016/S0168-8278(98)80001-9

DO - 10.1016/S0168-8278(98)80001-9

M3 - Article

VL - 29

SP - 173

EP - 183

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 2

ER -